Susquehanna International Group
ORMP icon

Susquehanna International Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Susquehanna International Group’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,400
Closed -$52.6K – 13487
2025
Q2 		$52.6K Buy
+23,400
New +$51.6K ﹤0.01% 12094
2024
Q1 		– Sell
-19,700
Closed -$45.5K – 13015
2023
Q4 		$45.5K Buy
+19,700
New +$42.1K ﹤0.01% 11747
2023
Q1 		– Sell
-112,500
Closed -$1.35M – 13220
2022
Q4 		$1.35M Buy
112,500
+92,100
+451% +$716K ﹤0.01% 5509
2022
Q3 		$132K Sell
20,400
-17,600
-46% -$142K ﹤0.01% 11408
2022
Q2 		$174K Sell
38,000
-31,700
-45% -$169K ﹤0.01% 10842
2022
Q1 		$603K Buy
69,700
+2,500
+4% +$25.6K ﹤0.01% 8477
2021
Q4 		$960K Sell
67,200
-108,100
-62% -$2.26M ﹤0.01% 7407
2021
Q3 		$3.85M Buy
175,300
+98,000
+127% +$1.67M ﹤0.01% 4430
2021
Q2 		$1.03M Buy
77,300
+9,400
+14% +$108K ﹤0.01% 7674
2021
Q1 		$690K Buy
67,900
+38,500
+131% +$316K ﹤0.01% 8701
2020
Q4 		$125K Buy
29,400
+6,000
+26% +$19.5K ﹤0.01% 10371
2020
Q3 		$61K Sell
23,400
-24,400
-51% -$85K ﹤0.01% 10147
2020
Q2 		$169K Sell
47,800
-6,500
-12% -$21.8K ﹤0.01% 9175
2020
Q1 		$165K Buy
54,300
+7,600
+16% +$33.3K ﹤0.01% 8902
2019
Q4 		$241K Buy
+46,700
New +$175K ﹤0.01% 8424
2016
Q4 		– Sell
-73,400
Closed -$533K – 9970
2016
Q3 		$533K Sell
73,400
-35,300
-32% -$274K ﹤0.01% 5954
2016
Q2 		$907K Buy
108,700
+69,000
+174% +$588K ﹤0.01% 5057
2016
Q1 		$264K Sell
39,700
-1,100
-3% -$7.37K ﹤0.01% 7469
2015
Q4 		$349K Buy
40,800
+17,100
+72% +$130K ﹤0.01% 7421
2015
Q3 		$130K Sell
23,700
-9,300
-28% -$58.5K ﹤0.01% 9011
2015
Q2 		$187K Buy
+33,000
New +$226K ﹤0.01% 9335
2015
Q1 		– Sell
-11,000
Closed -$50K – 9784
2014
Q4 		$50K Buy
+11,000
New +$72.3K ﹤0.01% 9365
2014
Q3 		– Sell
-12,200
Closed -$117K – 9791
2014
Q2 		$117K Buy
+12,200
New +$125K ﹤0.01% 9369

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Susquehanna International Group's ORMP Position: Q1 2026 in Review

Susquehanna International Group increased its Oramed Pharmaceuticals (ORMP) stake by 424% in Q1 2026, buying an estimated $374K and bringing the position to 136,218 shares worth $463K. The position accounts for ﹤0.01% of the portfolio, ranked #9875.

Susquehanna International Group first reported a position in ORMP in Q1 2014 and has held it in 30 quarters since. The position peaked at $2.23M in Q4 2022. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Susquehanna International Group held 136,218 shares of Oramed Pharmaceuticals worth $463K as of Q1 2026.
  • Susquehanna International Group bought 110,234 Oramed Pharmaceuticals shares in Q1 2026, an estimated $374K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9875 holding.
  • Susquehanna International Group first reported a position in Oramed Pharmaceuticals in Q1 2014 and has held it in 30 quarters since.
  • Susquehanna International Group's Oramed Pharmaceuticals position peaked at $2.23M in Q4 2022.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.